KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $57.0 million.

  • Pacira BioSciences' Free Cash Flow rose 1432.13% to $57.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.2 million, marking a year-over-year decrease of 3582.02%. This contributed to the annual value of $178.8 million for FY2024, which is 2814.94% up from last year.
  • Latest data reveals that Pacira BioSciences reported Free Cash Flow of $57.0 million as of Q3 2025, which was up 1432.13% from $9.3 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Free Cash Flow high stood at $57.0 million for Q3 2025, and its period low was -$992000.0 during Q1 2021.
  • Moreover, its 5-year median value for Free Cash Flow was $36.5 million (2022), whereas its average is $31.9 million.
  • As far as peak fluctuations go, Pacira BioSciences' Free Cash Flow tumbled by 9224.81% in 2021, and later soared by 242953.63% in 2022.
  • Over the past 5 years, Pacira BioSciences' Free Cash Flow (Quarter) stood at $14.0 million in 2021, then soared by 160.13% to $36.5 million in 2022, then increased by 25.29% to $45.8 million in 2023, then tumbled by 32.26% to $31.0 million in 2024, then soared by 83.67% to $57.0 million in 2025.
  • Its Free Cash Flow stands at $57.0 million for Q3 2025, versus $9.3 million for Q2 2025 and $26.9 million for Q1 2025.